Literature DB >> 15573918

The effect of H2 antagonists on proliferation and apoptosis in human colorectal cancer cell lines.

Shanmugarajah Rajendra1, Hugh Mulcahy, Stephen Patchett, Parveen Kumar.   

Abstract

Cimetidine is known to enhance the survival of gastro-intestinal cancer patients, though the mechanisms involved are incompletely understood. Postulated modes of action include blocking the proliferative effect of tumors and inhibiting T suppressor cell activity, both of which are thought to be mediated by histamine type 2 receptors. Apoptotic cell death may offer an alternative explanation for reduced cell growth. We aimed to examine the effects of histamine, cimetidine, and ranitidine on in vitro proliferation and apoptosis in two human colorectal cancer cell lines, Caco-2 and LoVo. A cell proliferation assay was used as an index of cell growth. Histamine receptor status was determined by quantifying cyclic adenosine monophosphate and apoptosis via DNA fragmentation. Results show that histamine (10(-5) to 10(-9) M) had no effect on the growth of either cell line. The proliferation of Caco-2 was inhibited by ranitidine (10(-7) M) alone and in combination with histamine. Cimetidine (10(-5) M) only suppressed the growth of Caco-2 in the presence of histamine. The H2 antagonists had no effect on LoVo irrespective of histamine. There was no accumulation of cyclic adenosine monophosphate in Caco-2 cells in response to histamine at a similar concentration. Apoptosis was induced in Caco-2 by both antisecretory drugs, and only ranitidine caused apoptotic cell death in LoVo cells. We conclude that cimetidine and ranitidine inhibit Caco-2 cancer cells in vitro, independently of the H2 receptor. In addition, both drugs induce apoptosis in the same cell line. Growth inhibition and apoptosis are likely to contribute to the tumor regressive properties of cimetidine and ranitidine in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15573918     DOI: 10.1023/b:ddas.0000043377.30075.ac

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Cimetidine and immunoreactivity.

Authors:  J Katoh; K Tsuchiya; W Sato; M Nakajima; Y Iida
Journal:  Lancet       Date:  1996-08-10       Impact factor: 79.321

2.  Effect of cimetidine on survival after gastric cancer.

Authors:  H Tønnesen; U Knigge; S Bülow; P Damm; K Fischerman; P Hesselfeldt; A Hjortrup; I K Pedersen; V M Pedersen; O J Siemssen
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

Review 3.  Cell death: the significance of apoptosis.

Authors:  A H Wyllie; J F Kerr; A R Currie
Journal:  Int Rev Cytol       Date:  1980

4.  Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression.

Authors:  K Kobayashi; S Matsumoto; T Morishima; T Kawabe; T Okamoto
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

Review 5.  Cimetidine: an immunomodulator.

Authors:  A Kumar
Journal:  DICP       Date:  1990-03

6.  Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine.

Authors:  S A Watson; L J Wilkinson; J F Robertson; J D Hardcastle
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

7.  Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01.

Authors:  B Fisher; N Wolmark; H Rockette; C Redmond; M Deutsch; D L Wickerham; E R Fisher; R Caplan; J Jones; H Lerner
Journal:  J Natl Cancer Inst       Date:  1988-03-02       Impact factor: 13.506

8.  Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth.

Authors:  W J Adams; J A Lawson; D L Morris
Journal:  Gut       Date:  1994-11       Impact factor: 23.059

9.  Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study.

Authors:  L B Svendsen; C Ross; U Knigge; H J Frederiksen; P Graversen; J Kjaergård; M Luke; H Stimpel; B H Sparsø
Journal:  Dis Colon Rectum       Date:  1995-05       Impact factor: 4.585

10.  Ranitidine as adjuvant treatment in colorectal cancer.

Authors:  H J Nielsen; I J Christensen; F Moesgaard; H Kehlet
Journal:  Br J Surg       Date:  2002-11       Impact factor: 6.939

View more
  7 in total

Review 1.  Histamine H₄ receptors in the gastrointestinal tract.

Authors:  A Deiteren; J G De Man; P A Pelckmans; B Y De Winter
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

2.  Histamine and histamine receptor regulation of gastrointestinal cancers.

Authors:  Lindsey Kennedy; Kyle Hodges; Fanyin Meng; Gianfranco Alpini; Heather Francis
Journal:  Transl Gastrointest Cancer       Date:  2012-10

3.  H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.

Authors:  Emir Hadzijusufovic; Barbara Peter; Karoline V Gleixner; Karina Schuch; Winfried F Pickl; Tuddow Thaiwong; Vilma Yuzbasiyan-Gurkan; Irina Mirkina; Michael Willmann; Peter Valent
Journal:  Exp Hematol       Date:  2010-06-01       Impact factor: 3.084

4.  Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent.

Authors:  Pan Pantziarka; Gauthier Bouche; Lydie Meheus; Vidula Sukhatme; Vikas P Sukhatme
Journal:  Ecancermedicalscience       Date:  2014-11-26

5.  Diamine Oxidase from White Pea (Lathyrus sativus) Combined with Catalase Protects the Human Intestinal Caco-2 Cell Line from Histamine Damage.

Authors:  Catherine Jumarie; Marilyne Séïde; Lucia Marcocci; Paola Pietrangeli; Mircea Alexandru Mateescu
Journal:  Appl Biochem Biotechnol       Date:  2017-01-20       Impact factor: 2.926

6.  Cimetidine promotes STUB1-mediated degradation of tumoral FOXP3 by activating PI3K-Akt pathway in gastric cancer.

Authors:  Lu Zhang; Qingya Li; Jianghao Xu; Guangli Sun; Zekuan Xu
Journal:  Ann Transl Med       Date:  2020-10

7.  Cimetidine-Based Cationic Amphiphiles for In Vitro Gene Delivery Targetable to Colon Cancer.

Authors:  Shireesha Manturthi; Dwaipayan Bhattacharya; Kalyani Rajesh Sakhare; Kumar Pranav Narayan; Srilakshmi V Patri
Journal:  ACS Omega       Date:  2022-08-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.